This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009) (CROSSOVER)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
PneumRx, Inc. Identifier:
First received: February 6, 2014
Last updated: May 27, 2016
Last verified: May 2016
Crossover study for patients who were randomized to the Control Group in CLN0009.

Condition Intervention Phase
Emphysema Device: LVRC System Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066

Resource links provided by NLM:

Further study details as provided by PneumRx, Inc.:

Primary Outcome Measures:
  • Difference from Baseline to 12 months in 6 MWT in cross over subjects from CLN0009 study. [ Time Frame: Up to 5 years post procedure ]
    This study provides the LVRC procedure to qualifying subjects who were enrolled as Control Subjects in and completed the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009. As stated above the study will measure the Difference from Baseline to 12 months in 6 MWT.

Enrollment: 102
Study Start Date: December 2013
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LVRC System Device: LVRC System

Detailed Description:
Provide LVRC procedure to qualifying subjects who were enrolled as Control Subjects in and completed the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009, and obtain safety and effectiveness data on these patients.

Ages Eligible for Study:   36 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject was enrolled as a Control Subject in and completed all required study assessments through the 12 month visit for the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009.
  2. Subject has post-bronchodilator FEV1 ≤45% predicted.
  3. Subject has residual volume (RV) ≥175% predicted.
  4. Subject has stopped smoking for at least 8 weeks prior to entering the study, as confirmed by a Cotinine test or other appropriate diagnostic test.
  5. Subject has read, understood and signed the Informed Consent form.
  6. Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.

Exclusion Criteria:

  1. Subject has severe homogeneous emphysema as determined by the Core Radiology Lab
  2. Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
  3. Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator, unless investigator can confirm by other means that subject does not have asthma.
  4. Subject has DLCO <20% of predicted.
  5. Subject has severe gas exchange abnormalities as defined by:

    PaCO2 >55 mm Hg PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg)

  6. Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.
  7. Subject has severe pulmonary hypertension. If pulmonary hypertension is present, "severe" is defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram.
  8. Subject has an inability to walk >140 meters (150 yards) in 6 minutes.
  9. Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
  10. Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
  11. Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
  12. Subject has clinically significant bronchiectasis.
  13. Subject has giant bullae >1/3 lung volume.
  14. Subject has had previous LVR surgery, lung transplantation, lobectomy, LVR devices or other devices to treat COPD in either lung.
  15. Subject has been involved in pulmonary drug or device studies within 30 days prior to this study, with the exception of the RENEW Study.
  16. Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.
  17. Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
  18. Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for seven (7) days prior to procedure.
  19. Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals.
  20. Subject has a known sensitivity to drugs required to perform bronchoscopy.
  21. Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
  22. Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02059057

  Show 25 Study Locations
Sponsors and Collaborators
PneumRx, Inc.
  More Information

Responsible Party: PneumRx, Inc. Identifier: NCT02059057     History of Changes
Other Study ID Numbers: CLN0016
Study First Received: February 6, 2014
Last Updated: May 27, 2016

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases processed this record on August 22, 2017